Nitroglycerin-induced nNOS increase in rat trigeminal nucleus caudalis is inhibited by systemic administration of lysine acetylsalicylate but not of sumatriptan
[en] Systemic administration of nitroglycerin (NTG), a nitric oxide (NO) donor, in migraineurs triggers after several hours an attack of which the precise mechanisms are unknown. We found previously in rats that nitroglycerin (10 mg/kg s.c.) is able to increase significantly after 4 h the number of neuronal nitric oxide synthase (nNOS)-immunoreactive neurones in the cervical part of trigeminal nucleus caudalis. In the present experiments, we demonstrate that the 5-HT1(B/D) agonist sumatriptan (0.6 mg/kg s.c.) does not alter this phenomenon when given before NTG. By contrast, pretreatment with lysine acetylsalicylate (50 mg/kg i.m.) attenuates the NTG-induced nNOS expression in the superficial laminae of trigeminal nucleus caudalis. These findings suggest that effect of NTG on nNOS at a high dosage may involve the cycloxygenase pathway and that activation of the peripheral 5-HT1(B/D) receptors is not able to modify this effect. These data could help to better understand the role of NO in the pathogenesis of headaches and the action of antimigraine drugs.
Disciplines :
Neurosciences & behavior Neurology
Author, co-author :
Pardutz, A.
Szatmari, E.
Vecsei, L.
Schoenen, Jean ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Neuro-anatomie
Language :
English
Title :
Nitroglycerin-induced nNOS increase in rat trigeminal nucleus caudalis is inhibited by systemic administration of lysine acetylsalicylate but not of sumatriptan
Sicuteri F, Del Bene E, Poggioni M, Bonazzi A. Unmasking latent dysnociception in healthy subjects. Headache 1987; 4:180-5.
Olesen J, Iversen HK, Thomsen LL. Nitric oxide supersensitivity. a possible molecular mechanism of migraine pain. Neuroreport 1993; 4:1027-30.
Iversen HK, Olesen J. Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs. Cephalalgia 1996; 16:412-8.
Ashina M, Bendtsen L, Jensen R, Olesen J. Nitric oxide-induced headache in patients with chronic tension-type headache. Brain 2000; 123:1830-7.
Saito S, Kidd GJ, Trapp BD, Dawson TM, Bredt DS, Wilson DA et al. Rat spinal cord neurons contain nitric oxide synthase. Neuroscience 1994; 59:447-56.
Lin Q, Palecek J, Paleckova V, Peng YB, Wu J, Cui M et al. Nitric oxide mediates the central sensitization of primate spinothalamic tract neurons. J Neurophysiol 1999; 81:1075-85.
Dohrn CS, Mullett MA, Price RH, Beitz AJ. Distribution of nitric oxide synthase-immunoreactive interneurons in the spinal trigeminal nucleus. J Comp Neurol 1994; 346:449-60.
Wang H, Nie H, Zhang RX, Qiao JT. Peripheral nitric oxide contributes to both formalin- and NMDA-induced activation of nociceptors: An immunocytochemical study in rats. J Neurosci Res 1999; 57:824-9.
Wu J, Fang L, Lin Q, Willis WD. Fos expression is induced by increased nitric oxide release in rat spinal cord dorsal horn. Neuroscience 2000; 96:351-7.
Ackerman S, Wiliamson DJ, Kaube H, Goadsby PJ. Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br J Pharmacol 2002; 137:62-8.
Lassen LH, Ashina M, Christiansen I, Ulrich V, Olesen J. Nitric oxide synthase inhibition in migraine. Lancet 1997; 349:401-2.
Ashina M. Nitric oxide synthase inhibitors for the treatment of chronic tension-type headache. Expert Opin Pharmacother 2002; 3:395-9.
Tassorelli C, Joseph SA. Systemic nitroglycerin induces Fos immunoreactivity in brainstem and forebrain structures of the rat. Brain Res 1995; 682:167-78.
Pardutz A, Krizbai I, Multon S, Vecsei L, Schoenen J. Systemic nitroglycerin increases nNOS levels in rat trigeminal nucleus caudalis. Neuroreport 2000; 14:3071-5.
De Vries P, Villalon CM, Saxena PR. Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. Eur J Pharmacol 1999; 375:61-74.
Hargreaves RJ, Shepheard SL. Pathophysiology of migraine-new insights. Can J Neurol Sci 1999; 26 Suppl 3:S12-9.
Buzzi MG, Moskowitz MA. Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia 1991; 11:165-8.
Lange R, Schwarz JA, Hohn M. Acetylsalicylic acid effervescent 1000 mg (Aspirin) in acute migraine attacks; a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 2000; 20:663-7.
Schoenen J. Tension-type headache. In: Diener HC, editor. Drug Treatment of Migraine and Other Headaches. Monographs in Clinical Neuroscience, Vol. 17. Basel: Karger, 2000:314-21.
Yaksh TL, Dirig DM, Conway CM, Svensson C, Luo ZD, Isakson PC. The acute antihyperalgesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. J Neurosci 2001; 21:5847-53.
Ma WY, Huang C, Dong Z. Inhibition of ultraviolet C irradiation-induced AP-1 activity by aspirin is through inhibition of JNKs but not erks or P38 MAP kinase. Int J Oncol 1998; 12:565-8.
Tassorelli C, Joseph SA, Nappi G. Neurochemical mechanisms of nitroglycerin-induced neuronal activation in rat brain: a pharmacological investigation. Neuropharmacology 1997; 36:1417-24.
Diener HC. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG Study Group. Cephalalgia 1999; 19:581-8.
Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-54.
Sousa AM, Prado WA. The dual effect of a nitric oxide donor in nociception. Brain Res 2001; 897:9-19.
Colasanti M, Suzuki H. The dual personality of no. Trends Pharmacol Sci 2000; 21:249-52.
Arvieu L, Mauborgne A, Bourgoin S, Oliver C, Feltz P, Hamon M et al. Sumatriptan inhibits the release of CGRP and substance P from the rat spinal cord. Neuroreport 1996; 7:1973-6.
Limmroth V, Katsarava Z, Liedert B, Guehring H, Schmitz K, Diener HC et al. An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system. Pain 2001; 92:101-6.
Knyihar-Csillik E, Tajti J, Samsam M, Sary G, Slezak S, Vecsei L. Effect of a serotonin agonist (sumatriptan) on the peptidergic innervation of the rat cerebral dura mater and on the expression of c-fos in the caudal trigeminal nucleus in an experimental migraine model. J Neurosci Res 1997; 48:449-64.
Fozard JR, Kalkman HO. 5-Hydroxytryptamine (5-HT) and the initiation of migraine: new perspectives. Naunyn Schmiedebergs Arch Pharmacol 1994; 3:225-9.
Schmuck K, Ullmer C, Kalkman HO, Probst A. Activation of meningeal 5-HT2B receptors: an early step in the generation of migraine headache? Eur J Neurosci 1996; 5:959-67.
Srikiatkhachorn A, Suwattanasophon C, Ruangpattanatawee U, Phansuwan-Pujito P. Wolff Award. 5-HT2A receptor activation and nitric oxide synthesis: a possible mechanism determining migraine attacks. Headache 2002; 7:566-74.
Srikiatkhachorn A, Govitrapong P, Limthavon C. Up-regulation of 5-HT2 serotonin receptor: a possible mechanism of transformed migraine. Headache 1994; 1:8-11.
Humphrey PP, Feniuk W, Marriott AS, Tanner RJ, Jackson MR, Tucker ML. Preclinical studies on the anti-migraine drug, sumatriptan. Eur Neurol 1991; 31:282-90.
Kaube H, Hoskin KL, Goadsby PJ. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br J Pharmacol 1993; 109:788-92.
Goadsby PJ, Hoskin KL. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT) 1B/ D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine? Pain 1996; 67:355-9.
Goadsby PJ, Knight Y. Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5-hydroxy-tryptamine (5-HT (1B/1D) receptors. Br J Pharmacol 1997; 122:918-22.
Banerjee M, Findley LJ. Sumatriptan in the treatment of acute migraine with aura. Cephalalgia 1992; 12:39-44.
Ross-Lee LM, Eadie MJ, Haezlewood V, Bochner F, Tyrere JH. Aspirin pharmatokinetics in migraine. The effect of metoclopramide. Eur J Clin Pharmacol 1983; 37:452-4.
Jones MG, Lever I, Bingham S, Read S, McMahon SB, Parsons A. Nitric oxide potentiates response of trigeminal neurones to durai or facial stimulation in the rat. Cephalalgia 2001; 6:643-55.
Beiche F, Brune K, Geisslinger G, Goppelt-Struebe M. Expression of cyclooxygenase isoforms in the rat spinal cord and their regulation during adjuvant-induced arthritis. Inflamm Res 1998; 47:482-7.
Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S et al. Interleukin-1 beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 2001; 410:471-5.
Maihofner C, Tegeder I, Euchenhofer C, deWitt D, Brune K, Bang R et al. Localization and regulation of cyclooxygenase-1 and - 2 and neuronal nitric oxide synthase in mouse spinal cord. Neuroscience 2000; 101:1093-108.
Gatti G, Barzaghi N, Attardo Parrinello G, Vitiello B, Perucca E. Pharmacokinetics of salicylic acid following administration of aspirin tablets and three different forms of soluble aspirin in normal subjects. Int J Clin Pharmacol Res 1989; 9:385-9.
Tortorici V, Vanegas H. Anti-nociception induced by systemic or PAG-microinjected lysine-acetylsalicylate in rats. Effects on tail-flick related activity of medullary off- and on-cells. Eur J Neurosci 1995; 7:1857-65.